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Abstract: AIMS To compare different treatments for non-alcoholic steatohepatitis (NASH) and to de-
termine an effectiveness hierarchy. MATERIALS AND METHODS We conducted a systematic review
and Bayesian network meta-analysis including randomized controlled trials or prospective trials with
at least 6 months’ follow-up and histologically proven NASH in adult participants. Monte Carlo sim-
ulations were performed, each generating 10 000 data points, and results are reported as medians and
95% credibility intervals (CrIs). A meta-regression was conducted to find the effects of body mass in-
dex (BMI) decrement or reduction of homeostatic model assessment of insulin resistance (HOMA-IR)
index on non-alcoholic fatty liver disease activity score (NAS) change. RESULTS The review identified
48 eligible trials comprising 2356 adults (55.6% men). Data were pooled using a random-effects model.
The most effective treatments in terms of NAS reduction per semester were pioglitazone and Roux-en-Y
gastric bypass (RYGB; -1.50 [95% CrI -2.08, -1.00] for pioglitazione and -1.00 [95% CrI -1.70, -0.32] for
RYGB). Pioglitazone was also the best therapy for steatosis and lobular inflammation reduction. RYGB
was the best treatment for hepatocellular ballooning reduction, whereas antioxidants appeared to be best
for fibrosis improvement. For each 1% decrement in BMI, NAS was reduced by 1.3% (฀ = 1.28%, P =
0.01). Conversely, a 1% reduction of HOMA-IR index reduced NAS by 0.3% (฀ = 0.31%, P < 0.001).
Treatments that were regarded as promising, such as elafibranor, simtuzumab, selonsertib, cenicriviroc,
obeticholic acid and liraglutide, did not reduce either NAS or liver fibrosis significantly. CONCLUSIONS
Pioglitazione and RYGB are the most effective therapies for NASH. Antioxidants may be effective in re-
ducing liver fibrosis. Weight loss and improvement of hepatic insulin resistance are promising approaches
in the treatment of NASH.
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